ARS Pharmaceuticals (SPRY) Assets (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Assets of $287.6 million for Q1 2026, down 12.23% sequentially from $327.7 million in Q4 2025, and down 12.14% YoY from $327.3 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Assets (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Assets for 7 years, with the latest figure at $287.6 million in Q1 2026.
- Quarterly Assets fell 12.14% year-over-year to $287.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $287.6 million (down 12.14% YoY) and the FY2025 annual result came in at $327.7 million, down 6.69% from the prior year.
- Assets declined to $287.6 million in Q1 2026 per SPRY's latest filing, from $327.7 million in the prior quarter.
- Over five years, Assets peaked at $372.8 million in Q3 2025 and troughed at $217.6 million in Q3 2024.
- A 5-year average of $283.4 million and a median of $281.4 million in 2022 frame the typical range for Assets.
- The widest YoY moves for Assets: up 358.02% in 2022, down 23.12% in 2022.
- Over 5 years, Assets stood at $281.4 million in 2022, then fell by 17.14% to $233.2 million in 2023, then soared by 50.59% to $351.2 million in 2024, then slipped by 6.69% to $327.7 million in 2025, then retreated by 12.23% to $287.6 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $287.6 million, $327.7 million, and $372.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 249.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 249.50 Mn |
| Mar 31, 2026 | 287.57 Mn |
| Dec 31, 2025 | 327.65 Mn |
| Sep 30, 2025 | 372.80 Mn |
| Jun 30, 2025 | 313.47 Mn |
| Mar 31, 2025 | 327.32 Mn |
| Dec 31, 2024 | 351.15 Mn |
| Sep 30, 2024 | 217.60 Mn |
| Jun 30, 2024 | 221.97 Mn |
| Mar 31, 2024 | 227.58 Mn |
| Dec 31, 2023 | 233.19 Mn |
| Sep 30, 2023 | 248.56 Mn |
| Jun 30, 2023 | 258.75 Mn |
| Mar 31, 2023 | 271.19 Mn |
| Dec 31, 2022 | 281.44 Mn |
| Sep 30, 2022 | 271.06 Mn |
| Jun 30, 2022 | 294.00 Mn |
| Mar 31, 2022 | 312.47 Mn |
| Dec 31, 2021 | 61.45 Mn |
| Sep 30, 2021 | 352.56 Mn |